We recently heard the interim high-level results from phase 3 clinical trials of the Oxford AstraZeneca COVID-19 vaccine in the UK and Brazil.
The scientists have now published the results in the Lancet.
Journalists dialled in to this briefing to hear from the scientists involved and ask them their questions.
Prof Andrew Pollard, Director of the Oxford Vaccine Group, Department of Paediatrics, University of Oxford
Prof Sarah Gilbert, Saïd Professorship of Vaccinology, Jenner Institute, Nuffield Department of Medicine, University of Oxford
Pascal Soriot, Chief Executive Officer, AstraZeneca
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca
This Briefing was accompanied by an SMC Roundup of Comments.